{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:44:07Z","timestamp":1777416247298,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.thromres.2018.05.004","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T02:05:06Z","timestamp":1525658706000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2608-6722","authenticated-orcid":false,"given":"Kelvin","family":"Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javad","family":"Shahidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Soldatenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffael","family":"Kurek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2018.05.004_bb0005","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","article-title":"Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study","volume":"162","author":"Heit","year":"2002","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.thromres.2018.05.004_bb0010","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2018.05.004_bb0020","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials","volume":"23","author":"Petrelli","year":"2012","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.thromres.2018.05.004_bb0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1160\/TH05-10-0694","article-title":"Trousseau's syndrome - what is the evidence? A population-based autopsy study","volume":"95","author":"\u00d6gren","year":"2006","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.05.004_bb0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0035","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.05.004_bb0040","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"29","key":"10.1016\/j.thromres.2018.05.004_bb0045","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0050","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1002\/cncr.24596","article-title":"Venous thromboembolism and nonsmall cell lung cancer. A pooled analysis of National Cancer Institute of Canada Clinical Trials Group Trials","author":"Hicks","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/125706","article-title":"The incidence and predictors of thromboembolic events in patients with lung cancer","author":"Kadlec","year":"2014","journal-title":"Sci. World J."},{"issue":"6","key":"10.1016\/j.thromres.2018.05.004_bb0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.neo.7900263","article-title":"The hypercoagulable state of malignancy: pathogenesis and current debate","volume":"4","author":"Caine","year":"2002","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.thromres.2018.05.004_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0070","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0075","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.30280","article-title":"Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab)","volume":"139","author":"Miroddi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0080","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0085","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(15)70046-X","article-title":"Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study","volume":"16","author":"Paz-Ares","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.thromres.2018.05.004_bb0090","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.cllc.2017.02.002","article-title":"An open-label, randomized, controlled phase II study of paclitaxel-carboplatin chemotherapy with necitumumab versus paclitaxel-carboplatin alone in first-line treatment of patients with stage IV squamous non-small-cell lung cancer","volume":"18","author":"Spigel","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0095","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 8","key":"10.1016\/j.thromres.2018.05.004_bb0110","article-title":"Primary efficacy and safety results of spectrum, a phase 3 trial in patients (PTS) with recurrent and\/or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (PMAB)","volume":"21","author":"Vermorken","year":"2010","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.thromres.2018.05.004_bb0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clcc.2011.05.006","article-title":"Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil\/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer","volume":"11","author":"Saltz","year":"2012","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2012.385","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2018.05.004_bb0125","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1097\/JTO.0b013e3182a7d1da","article-title":"A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first line treatment of advanced non-small-cell lung cancer","volume":"8","author":"Crawford","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0130","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.thromres.2018.05.004_bb0135","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0140","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S1470-2045(13)70473-X","article-title":"Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial","volume":"14","author":"Kim","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0145","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","article-title":"Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial","volume":"14","author":"Crosby","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0150","first-page":"110","article-title":"A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?","volume":"2178\u201386","author":"Maughan","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0155","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/cncr.28767","article-title":"A randomized phase 2 trial of gemcitabine\/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma","volume":"120","author":"Hussain","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0160","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomized phase 3 trial","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0165","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clcc.2013.12.002","article-title":"Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147","volume":"13","author":"Huang","year":"2014","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0170","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0175","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.thromres.2018.05.004_bb0180","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2010.29.2847","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II\/III REAL-3 trial","volume":"28","author":"Okines","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","article-title":"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial","volume":"14","author":"Vermorken","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0190","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.05.004_bb0200","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.21277","article-title":"Hemostatic complications of angiogenesis inhibitors in cancer patients","volume":"83","author":"Elice","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0205","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000078469.07362.E6","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2018.05.004_bb0210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/bjc.2016.143","article-title":"Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data","volume":"115","author":"Walker","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.thromres.2018.05.004_bb0215","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0049-3848(17)30062-2","article-title":"Women, thrombosis, and cancer: a gender-specific analysis","volume":"151","author":"Farge","year":"2017","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.thromres.2018.05.004_bb0220","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2018.05.004_bb0225","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jth.13378","article-title":"Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer","volume":"14","author":"Mansfield","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2018.05.004_bb0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ygyno.2014.04.046","article-title":"The survival detriment of venous thromboembolism with epithelial ovarian cancer","volume":"134","author":"Gunderson","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0235","author":"Streiff"},{"issue":"17","key":"10.1016\/j.thromres.2018.05.004_bb0240","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.05.004_bb0245","series-title":"American College of Chest Physicians Evidence Based Clinical Practice Guidelines","article-title":"Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis","volume":"141(2 Suppl)","author":"Kahn","year":"2012"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818303359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818303359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:47:57Z","timestamp":1530578877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818303359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":47,"alternative-id":["S0049384818303359"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.05.004","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}